Multitarget FAAX and COX inhibitors
The proposed invention integrates into the selective inhibitors field which represent an important progress in pharmacological research. Specifically, it refers to novel active compounds based on multitarget inhibitors, along with therapeutical application of the multitarget inhibitors in particular in the prevention and treatment of cancer and in the pain treatment.
Inflammatory pathologies afflict hundreds of millions of people worldwide. Yet the use of current therapies is limited by potentially serious side effects, such as gastric damage, kidney damage and an increased risk of stroke.
The invention refers to new compounds that simultaneously inhibit the enzymes Hydrolase of fatty acid amides (FAAH), Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2). FAAH inhibitors might have an analgesic action without side effects. COX-1 is the main cause of gastric damage. COX-2 is instead an enzyme causing a wide range of inflammatory processes in the body. Thus, its inhibition could help treat the symptoms of various disorders. As a result, the patented compounds find application in the medical field, in the treatment of pathological conditions where simultaneous inhibition of FAAH, COX-1 and/or COX-2 is desirable because they are effective in the treatment of inflammation and related conditions and their administrations result in a reduced risk of side effects in humans.
- Treatment of cancer and precancerous conditions;
- Treatment of inflammatory diseases, pain, eating disorders and anxiety;
- Treatment of cardiovascular pathologies.
- Reduced risk of side effects during the inflammation treatment.